ZyVersa Therapeutics, Inc.

NasdaqCM:ZVSA Stock Report

Market Cap: US$2.9m

ZyVersa Therapeutics Management

Management criteria checks 2/4

ZyVersa Therapeutics' CEO is Steve Glover, appointed in Dec 2022, has a tenure of 2.08 years. total yearly compensation is $993.22K, comprised of 55.4% salary and 44.6% bonuses, including company stock and options. directly owns 0.056% of the company’s shares, worth $1.62K. The average tenure of the management team and the board of directors is 2.1 years and 2.1 years respectively.

Key information

Steve Glover

Chief executive officer

US$993.2k

Total compensation

CEO salary percentage55.4%
CEO tenure2.1yrs
CEO ownership0.06%
Management average tenure2.1yrs
Board average tenure2.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Glover's remuneration changed compared to ZyVersa Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$22m

Mar 31 2024n/an/a

-US$106m

Dec 31 2023US$993kUS$550k

-US$106m

Sep 30 2023n/an/a

-US$88m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$451k

-US$14m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$10m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$2mUS$451k

-US$8m

Dec 31 2020US$451kUS$451k

-US$13m

Compensation vs Market: Steve's total compensation ($USD993.22K) is above average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Glover (64 yo)

2.1yrs

Tenure

US$993,217

Compensation

Mr. Stephen C. Glover, also known as Steve, serves as Chairman of the Board at Ambrx Biopharma Inc. since May 18, 2023. He has been a Director of Incon Co., Ltd. since December 2018.Mr. Glover is a Co-Fou...

Leadership Team

NamePositionTenureCompensationOwnership
Stephen Glover
Co-Founder2.1yrsUS$993.22k0.056%
$ 1.6k
Peter Wolfe
CFO & Secretary2.1yrsUS$573.36k0.0054%
$ 157.5
Karen Cashmere
Chief Commercial Officer2.1yrsUS$486.69k0%
$ 0
Melda Uzbil O'connell
Senior Vice President of Corporate Developmentno datano datano data
Pablo Guzman
Chief Medical Officer2yrsno data0.0032%
$ 94.2

2.1yrs

Average Tenure

68yo

Average Age

Experienced Management: ZVSA's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Glover
Co-Founder2.1yrsUS$993.22k0.056%
$ 1.6k
Pablo Guzman
Chief Medical Officerno datano data0.0032%
$ 94.2
Gregory Freitag
Independent Director2yrsUS$80.14k0%
$ 0
Robert Finizio
Independent Director2.1yrsUS$80.64k0%
$ 0
James Sapirstein
Independent Director2yrsUS$72.90k0%
$ 0
Marlene Haffner
Member of Scientific Advisory Boardno datano datano data
Alessia Fornoni
Member of Scientific Advisory Boardno datano datano data
Helen Bramlett
Member of Scientific Advisory Boardno datano datano data
Juan de Rivero Vaccari
Member of Scientific Advisory Boardno datano datano data
Robert Keane
Member of Scientific Advisory Boardno datano datano data
Sharon Adler
Member of Scientific Advisory Boardno datano datano data
Min-Chul Park
Independent Director2.1yrsUS$66.39k0%
$ 0

2.1yrs

Average Tenure

63yo

Average Age

Experienced Board: ZVSA's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 20:10
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ZyVersa Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerNOBLE Capital Markets, Inc.